



IFAKARA HEALTH INSTITUTE
research | training | services

Design of PfSPZ-CVac (IV) IHI, Bagamoyo, Tanzania

Seif Shekalaghe



Goal

Establish a regimen of PfSPZ Challenge with chloroquine, with *Plasmodium falciparum* sporozoites administered intravenously (IV), that:

1. Is safe and well tolerated
2. Provides consistent sterile protection against homologous and heterologous Controlled Human Malaria Infection (CHMI) in healthy adult subjects

Design of PfSPZ-CVac (IV)

	Week 0	Week 4	Week 8	Week 12	Week 16
Group 1 (N=3)	3,200 PfSPZ	12,800 PfSPZ	51,200 PfSPZ		
Group 2 (N=15)		12,800 PfSPZ	12,800 PfSPZ	12,800 PfSPZ	
Group 3 (N=15)			51,200 PfSPZ	51,200 PfSPZ	51,200 PfSPZ

- CHMI 1. Homologous (NF54 IV 3,200) = Treatment with Malarone if positive
- CHMI 2. Heterologous (7G8 IV 3,200) = Treatment with Coartem if positive

All non positives treated with Coartem Day 28

Collaboration & partnerships

- Ifakara Health Institute
- Swiss TPH
- Institute of Tropical Medicine, University of Tubingen
- Albert Schweitzer Hospital
- Radboud University Nijmegen Medical Center
- Sanaria Inc
- NIH Vaccine Research center

Funded by : EVI

THANK YOU